Draft research and innovation agenda proposes objectives around surveillance, treatment and more
A planned EU research and innovation partnership on antimicrobial resistance has set out draft R&I goals, including around surveillance and treatment.
AMR occurs when infectious organisms such as bacteria, fungi and viruses evolve the ability to withstand medical treatment. It is a huge and growing global concern, with about 1.27 million people thought to have died from bacterial AMR in 2019, according to one estimate cited by the draft R&I agenda of the European Partnership on One Health Antimicrobial Resistance.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.